Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development and Initial Validation of the Quality of life Evaluation in <i>NF2</i> -related Schwannomatosis Trials (QUEST) Assessment.

medRxiv : the preprint server for health sciences·2026

Same author

Reliability of a modified mini balance evaluation systems test (Mini-BESTest) in NF2-related schwannomatosis.

Gait & posture·2026

Same author

Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation.

Theranostics·2026

Same author

NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss.

Nature communications·2026

Same author

Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Obesity and Obstructive Sleep Apnea: Impact on Medical and Surgical Management.

Otolaryngologic clinics of North America·2026

Same journal

Little Tube; Big Problems: Eustachian Tube Dysfunction.

Otolaryngologic clinics of North America·2026

Same journal

Current State of Button Battery Ingestion Injuries.

Otolaryngologic clinics of North America·2026

Same journal

Diagnostic Algorithm for Eustachian Tube Dysfunction and Indications for Balloon Dilation of the Eustachian Tube.

Otolaryngologic clinics of North America·2026

Same journal

Patulous Eustachian Tube Dysfunction.

Otolaryngologic clinics of North America·2026

Same journal

Revisiting Eustachian Tube Anatomy and Physiology.

Otolaryngologic clinics of North America·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 23, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Chemotherapy: present and future.

Anna R Terry¹, Scott R Plotkin

¹Department of Neurosurgery, Massachusetts General Hospital, White 502, 55 Fruit Street, Boston, MA 02114, USA.

Otolaryngologic Clinics of North America

|April 10, 2012

Summary

This summary is machine-generated.

Vestibular schwannomas (VS), common brain tumors, lack effective medical treatments. This review explores VS molecular biology and potential chemotherapy targets to improve patient outcomes.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Related Experiment Videos

Last Updated: May 23, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Area of Science:

Neuro-oncology
Neurosurgery
Medical Genetics

Background:

Vestibular schwannomas (VS) are common central nervous system tumors.
Bilateral VS characterize neurofibromatosis type II, often causing deafness and nerve deficits.
Current treatments (surgery, radiation) have significant morbidity, necessitating medical therapies.

Purpose of the Study:

To review current Vestibular Schwannoma therapies.
To summarize VS molecular biology and identify chemotherapy targets.
To recommend clinical endpoints for future drug trials.

Main Methods:

Literature review of standard VS therapies.
Summary of molecular pathways implicated in VS development.
Analysis of anti-VEGF and anti-EGFR agent efficacy.
Definition of clinical endpoints for drug development.

Main Results:

Standard therapies include surgery and radiation, with associated morbidities.
Molecular targets for chemotherapy are being investigated.
Anti-VEGF and anti-EGFR agents show potential but require further study.
Specific clinical endpoints are crucial for evaluating new treatments.

Conclusions:

Effective medical therapies for Vestibular Schwannomas are urgently needed.
Understanding VS molecular biology is key to developing targeted treatments.
Future research should focus on novel chemotherapeutic agents and defined clinical trials.